Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease

Vaccine

Volumn 33, Issue 24, 2015, Pages 2823-2829

  Prescott, Joseph ^a   DeBuysscher, Blair L ^a,b   Feldmann, Friederike ^a   Gardner, Donald J ^a   Haddock, Elaine ^a   Martellaro, Cynthia ^a   Scott, Dana ^a   Feldmann, Heinz ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF MONTANA   (United States)

Author keywords

Immune response; Nipah virus; Paramyxovirus; Vaccine; Vesicular stomatitis virus

Indexed keywords

UNCLASSIFIED DRUG; VESICULOVIRUS VACCINE; VIRUS GLYCOPROTEIN; VIRUS RNA; VIRUS VACCINE; DNA VACCINE; GLYCOPROTEIN; LIVE VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHLOROCEBUS AETHIOPS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; MALE; NIPAH VIRUS; NIPAH VIRUS INFECTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VACCINATION; VESICULOVIRUS; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TITRATION; ANIMAL; CELLULAR IMMUNITY; DISEASE MODEL; GENETICS; HAMSTER; HENIPAVIRUS INFECTIONS; IMMUNOLOGY; PHYSIOLOGY; VIREMIA; VIROLOGY; VIRUS LOAD;

ANIMALS; CERCOPITHECUS AETHIOPS; CRICETINAE; DISEASE MODELS, ANIMAL; FEMALE; GLYCOPROTEINS; HENIPAVIRUS INFECTIONS; IMMUNITY, CELLULAR; MALE; NIPAH VIRUS; VACCINATION; VACCINES, ATTENUATED; VACCINES, DNA; VESICULOVIRUS; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIRAL VACCINES; VIREMIA;

EID: 84929297020     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.089     Document Type: Article

References (34)

1. Chua K.B., Bellini W.J., Rota P.A., Harcourt B.H., Tamin A., Lam S.K., et al. Nipah virus: a recently emergent deadly paramyxovirus. Science 2000, 288:1432-1435. 8529 [pii].
2. Goh K.J., Tan C.T., Chew N.K., Tan P.S., Kamarulzaman A., Sarji S.A., et al. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. N Engl J Med 2000, 342:1229-1235. MJBA-421701 [pii] 10.1056/NEJM200004273421701.
3. Quddus R., Alam S., Majumdar M.A., Anwar S., Khan M.R., Zahid Mahmud Khan A.K.S., et al. A report of 4 patients with Nipah encephalitis from Rajbari district, Bangladesh in the January 2004 outbreak. Neurol Asia 2004, 9:33-37.
4. Hsu V.P., Hossain M.J., Parashar U.D., Ali M.M., Ksiazek T.G., Kuzmin I., et al. Nipah virus encephalitis reemergence, Bangladesh. Emerg Infect Dis 2004, 10:2082-2087. 10.3201/eid1012.040701.
5. Biswas T. Nipah virus research review of infection features and recurrent outbreaks. J Young Med Res 2013, 1:1. 10.7869/jymr.10.
6. Field H.E., Mackenzie J.S., Daszak P. Henipaviruses: emerging paramyxoviruses associated with fruit bats. Curr Top Microbiol Immunol 2007, 315:133-159.
7. Halpin K., Hyatt A.D., Fogarty R., Middleton D., Bingham J., Epstein J.H., et al. Pteropid bats are confirmed as the reservoir hosts of henipaviruses: a comprehensive experimental study of virus transmission. Am J Trop Med Hyg 2011, 85:946-951. 10.4269/ajtmh.2011.10-0567.
8. Rahman M.A., Hossain M.J., Sultana S., Homaira N., Khan S.U., Rahman M., et al. Date palm sap linked to Nipah virus outbreak in Bangladesh, 2008. Vector Borne Zoonotic Dis 2012, 12:65-72. 10.1089/vbz.2011.0656.
9. Luby S.P., Hossain M.J., Gurley E.S., Ahmed B.N., Banu S., Khan S.U., et al. Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001-2007. Emerg Infect Dis 2009, 15:1229-1235.
10. ICDDRB Person-to-person transmission of Nipah virus during outbreak in Faridpur District, 2004. Heal Sci Bull 2004, 2:5-9.
11. Gurley E.S., Montgomery J.M., Hossain M.J., Bell M., Azad A.K., Islam M.R., et al. Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg Infect Dis 2007, 13:1031-1037.
12. Luby S.P., Gurley E.S., Hossain M.J. Transmission of human infection with Nipah virus. Clin Infect Dis 2009, 49:1743-1748. 10.1086/647951.
13. Homaira N., Rahman M., Hossain M.J., Epstein J.H., Sultana R., Khan M.S., et al. Nipah virus outbreak with person-to-person transmission in a district of Bangladesh, 2007. Epidemiol Infect 2010, 138:1630-1636. S0950268810000695 [pii] 10.1017/S0950268810000695.
14. Chong H.T., Kunjapan S.R., Thayaparan T., Tong J., Petharunam V., Jusoh M.R., et al. Nipah encephalitis outbreak in Malaysia, clinical features in patients from Seremban. Can J Neurol Sci 2002, 29:83-87.
15. Suhailah Abdullah L-Y.C. Late-onset Nipah virus encephalitis 11 years after the initial outbreak: a case report. Neurol Asia 2012, 17:71-74.
16. Prescott J., de Wit E., Feldmann H., Munster V.J. The immune response to Nipah virus infection. Arch Virol 2012, 157:1635-1641. 10.1007/s00705-012-1352-5.
17. Debuysscher B.L., Scott D., Marzi A., Prescott J., Feldmann H. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins. Vaccine 2014, 32:2637-2644. 10.1016/j.vaccine.2014.02.087.
18. Brown K.S., Safronetz D., Marzi A., Ebihara H., Feldmann H. Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus. J Virol 2011, 85:12781-12791. 10.1128/JVI.00794-11.
19. Geisbert T.W., Daddario-DiCaprio K.M., Hickey A.C., Smith M.A., Chan Y.P., Wang L.F., et al. Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection. PLoS ONE 2010, 5:e10690. 10.1371/journal.pone.0010690.
20. DeBuysscher B.L., de Wit E., Munster V.J., Scott D., Feldmann H., Prescott J. Comparison of the pathogenicity of Nipah virus isolates from Bangladesh and Malaysia in the Syrian hamster. PLoS Negl Trop Dis 2013, 7:e2024. 10.1371/journal.pntd.0002024.
21. De Wit E., Bushmaker T., Scott D., Feldmann H., Munster V.J. Nipah virus transmission in a hamster model. PLoS Negl Trop Dis 2011, 5:e1432. 10.1371/journal.pntd.0001432.
22. Bossart K.N., Rockx B., Feldmann F., Brining D., Scott D., LaCasse R., et al. A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci Transl Med 2012, 4:146ra107. 10.1126/scitranslmed.3004241.
23. Yoneda M., Georges-Courbot M-C., Ikeda F., Ishii M., Nagata N., Jacquot F., et al. Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge. PLoS ONE 2013, 8:e58414. 10.1371/journal.pone.0058414.
24. Bossart K.N., Geisbert T.W., Feldmann H., Zhu Z., Feldmann F., Geisbert J.B., et al. A neutralizing human monoclonal antibody protects African green monkeys from Hendra virus challenge. Sci Transl Med 2011, 3:105ra103. 10.1126/scitranslmed.3002901.
25. Geisbert T.W., Mire C.E., Geisbert J.B., Chan Y-P., Agans K.N., Feldmann F., et al. Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody. Sci Transl Med 2014, 6:242ra82. 10.1126/scitranslmed.3008929.
26. Jones S.M., Feldmann H., Ströher U., Geisbert J.B., Fernando L., Grolla A., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005, 11:786-790. 10.1038/nm1258.
27. Geisbert T.W., Daddario-Dicaprio K.M., Geisbert J.B., Reed D.S., Feldmann F., Grolla A., et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 2008, 26:6894-6900. 10.1016/j.vaccine.2008.09.082.
28. Garbutt M., Liebscher R., Wahl-Jensen V., Jones S., Moller P., Wagner R., et al. Properties of replication-competent vesicular stomatitis virus Vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004, 78:5458-5465. 10.1128/JVI.78.10.5458-5465.2004.
29. Daddario-DiCaprio K.M., Geisbert T.W., Ströher U., Geisbert J.B., Grolla A., Fritz E.A., et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006, 367:1399-1404. 10.1016/S0140-6736(06)68546-2.
30. Feldmann H., Jones S.M., Daddario-DiCaprio K.M., Geisbert J.B., Ströher U., Grolla A., et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007, 3:e2. 10.1371/journal.ppat.0030002.
31. Geisbert T.W., Daddario-DiCaprio K.M., Williams K.J.N., Geisbert J.B., Leung A., Feldmann F., et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008, 82:5664-5668. 10.1128/JVI.00456-08.
32. Tsuda Y., Safronetz D., Brown K., LaCasse R., Marzi A., Ebihara H., et al. Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection. J Infect Dis 2011, 204(Suppl):S1090-S1097. 10.1093/infdis/jir379.
33. Marzi A., Engelmann F., Feldmann F., Haberthur K., Shupert W.L., Brining D., et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci USA 2013, 110:1893-1898. 10.1073/pnas.1209591110.
34. Homaira N., Rahman M., Hossain M.J., Nahar N., Khan R., Podder G., et al. Cluster of Nipah virus infection, Kushtia district, Bangladesh, 2007. PLoS ONE 2010, 5:e13570. 10.1371/journal.pone.0013570.